📣 VC round data is live. Check it out!
- Public Comps
- Schrödinger
Schrödinger Valuation Multiples
Discover Schrödinger's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Vitec Software, Sphere, MedicalSystem Technology, iFLYHealth and more.
Schrödinger Overview
About Schrödinger
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
Founded
1995
HQ

Employees
850
Website
Financials (LTM)
EV
$824M
Valuation Multiples
Start free trialSchrödinger Financials
Schrödinger reported last 12-month revenue of $247M and negative EBITDA of ($140M).
In the same LTM period, Schrödinger generated $133M in gross profit, ($140M) in EBITDA losses, and had net loss of ($126M).
Revenue (LTM)
Schrödinger P&L
In the most recent fiscal year, Schrödinger reported revenue of $256M and EBITDA of ($139M).
Schrödinger is unprofitable as of last fiscal year, with gross margin of 56%, EBITDA margin of (54%), and net margin of (40%).
Financial data powered by Morningstar, Inc.
Schrödinger Stock Performance
Schrödinger has current market cap of $1B, and enterprise value of $824M.
Market Cap Evolution
Schrödinger's stock price is $14.94.
Schrödinger share price decreased by 1.7% in the last 30 days, and by 25.7% in the last year.
Schrödinger has an EPS (earnings per share) of $-1.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $824M | $1B | -5.5% | -1.7% | 31.5% | -25.7% | $-1.38 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSchrödinger Valuation Multiples
Schrödinger trades at 3.3x EV/Revenue multiple, and (5.9x) EV/EBITDA.
EV / Revenue (LTM)
Schrödinger Financial Valuation Multiples
As of June 4, 2026, Schrödinger has market cap of $1B and EV of $824M.
Schrödinger has a P/E ratio of (8.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Schrödinger Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Schrödinger Margins & Growth Rates
Schrödinger decreased revenue by 8% but EBITDA grew by 2% in the last fiscal year.
In the most recent fiscal year, Schrödinger reported gross margin of 56%, EBITDA margin of (54%), and net margin of (40%).
Schrödinger Margins
Schrödinger Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Schrödinger Operational KPIs
Schrödinger's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.
Schrödinger's Rule of 40 is (69%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Schrödinger's Rule of X is (81%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Schrödinger Competitors
Schrödinger competitors include Vitec Software, Sphere, MedicalSystem Technology, iFLYHealth, U.S. Physical Therapy, Hangzhou Pinming Software, Indegene, B-Soft Co., PHC Holdings and RaySearch Labs.
Most Schrödinger public comparables operate across Healthcare Software, B2B SaaS, Vertical SaaS, HealthTech and BioTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.6x | 3.5x | 9.2x | 9.5x | |||
| 19.2x | - | 201.2x | - | |||
| 21.4x | 19.2x | 72.6x | 83.5x | |||
| 9.3x | 8.3x | (240.0x) | (233.9x) | |||
| 1.6x | 1.6x | 11.7x | 13.0x | |||
| 14.1x | - | 110.1x | - | |||
| 3.1x | 3.0x | 16.6x | 17.0x | |||
| 5.5x | 5.3x | (24.2x) | (51.4x) | |||
This data is available for Pro users. Sign up to see all Schrödinger competitors and their valuation data. Start Free Trial | ||||||
Schrödinger VC Funding History
Before going public, Schrödinger raised $155M in total equity funding, across 3 rounds.
Schrödinger Funding Rounds
Acquisitions by Schrödinger
Schrödinger has acquired 1 company to date.
Last acquisition by Schrödinger was on January 18th 2022. Schrödinger acquired Xtal BioStructures for $6M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Schrödinger
| Description | Xtal BioStructures is a Markhams-based provider of biopharmaceutical protein services including crystallization, structure determination, and purification. The company supports drug discovery efforts with X-ray crystallography, synchrotron beamline access, and recombinant protein production for clients in oncology and infectious disease research. |
| HQ Country | |
| HQ City | Boston, MA |
| Deal Date | 18 Jan 2022 |
| Valuation | $6M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Schrödinger acquisitions and their M&A valuation multiples. Start Free Trial | |
Investments by Schrödinger
Schrödinger has invested in 3 companies to date.
Latest investment by Schrödinger was on May 13th 2024. Schrödinger invested in Ajax Therapeutics in their $95M Series C round (EV/Revenue multiple available to Pro users).
Latest Investments by Schrödinger
| Description | Ajax Therapeutics is a New York City-based biotechnology company that employs computational chemistry and structure-based design to create small molecule inhibitors for hematologic malignancies. The firm targets mutated kinases driving myeloproliferative neoplasms, with its lead candidate in Phase 1 trials. Ajax Therapeutics collaborates with Bristol Myers Squibb and maintains a pipeline addressing sickle cell disease. | Ajax Therapeutics is a New York City-based biotechnology company that employs computational chemistry and structure-based design to create small molecule inhibitors for hematologic malignancies. The firm targets mutated kinases driving myeloproliferative neoplasms, with its lead candidate in Phase 1 trials. Ajax Therapeutics collaborates with Bristol Myers Squibb and maintains a pipeline addressing sickle cell disease. | Morphic Therapeutic is a NASDAQ-listed biotechnology company developing oral small-molecule integrin inhibitors for autoimmune diseases, fibrosis, cancer, and cardiovascular conditions. Headquartered in Waltham, Massachusetts, since 2014, it advances MMPD2 inhibitors through Phase 2 trials for inflammatory bowel disease, partnering with Roche for co-development. | Nimbus Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, developing small molecule therapeutics for metabolic diseases, cancer, and immune-inflammatory disorders. The firm uses computational design for highly selective inhibitors, with a pipeline including clinical candidates in immunology partnered with Celgene. | |
| HQ Country | |||||
| HQ City | - | - | Boston, MA | Boston, MA | |
| Deal Date | 13 May 2024 | 1 Jun 2021 | 25 Sep 2018 | 5 Jun 2018 | |
| Round | Series C | Undisclosed stage | Series B | Series C | |
| Raised | $95M | $40M | $80M | $65M | |
| Investors | Boxer Capital; EcoR1 Capital; Eli Lilly & Company Foundation; Goldman Sachs Asset Management; Inning One Ventures; Point72 Ventures; RA Capital Management; Schrödinger; Vivo Capital | Boxer Capital; EcoR1 Capital; Inning One Ventures; Memorial Sloan Kettering Cancer Center; NYU Langone Health; Schrödinger | EcoR1 Capital; Invus; Novo Holdings; Omega Funds; Pfizer Venture Investments; Polaris Partners; Schrödinger; ShangPharma; SR One; Timothy A. Springer | Atlas Venture; Bill Gates; Lightstone Ventures; Lilly Ventures; Pfizer Venture Investments; Schrödinger; SR One | |
| Valuation | $193M | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Schrödinger investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Schrödinger
| When was Schrödinger founded? | Schrödinger was founded in 1995. |
| Where is Schrödinger headquartered? | Schrödinger is headquartered in United States. |
| How many employees does Schrödinger have? | As of today, Schrödinger has over 850 employees. |
| Who is the CEO of Schrödinger? | Schrödinger's CEO is Ramy Farid. |
| Is Schrödinger publicly listed? | Yes, Schrödinger is a public company listed on Nasdaq. |
| What is the stock symbol of Schrödinger? | Schrödinger trades under SDGR ticker. |
| When did Schrödinger go public? | Schrödinger went public in 2020. |
| Who are competitors of Schrödinger? | Schrödinger main competitors include Vitec Software, Sphere, MedicalSystem Technology, iFLYHealth, U.S. Physical Therapy, Hangzhou Pinming Software, Indegene, B-Soft Co., PHC Holdings, RaySearch Labs. |
| What is the current market cap of Schrödinger? | Schrödinger's current market cap is $1B. |
| What is the current revenue of Schrödinger? | Schrödinger's last 12 months revenue is $247M. |
| What is the current revenue growth of Schrödinger? | Schrödinger revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Schrödinger? | Current revenue multiple of Schrödinger is 3.3x. |
| Is Schrödinger profitable? | No, Schrödinger is not profitable. |
| What is the current EBITDA of Schrödinger? | Schrödinger has negative EBITDA and is not profitable. |
| What is Schrödinger's EBITDA margin? | Schrödinger's last 12 months EBITDA margin is (57%). |
| What is the current EV/EBITDA multiple of Schrödinger? | Current EBITDA multiple of Schrödinger is (5.9x). |
| How many companies Schrödinger has acquired to date? | As of June 2026, Schrödinger has acquired 1 company. |
| What was the largest acquisition by Schrödinger? | $6M acquisition of Xtal BioStructures on 18th January 2022 was the largest M&A Schrödinger has done to date. |
| What companies Schrödinger acquired? | Schrödinger acquired Xtal BioStructures. |
| In how many companies Schrödinger has invested to date? | As of June 2026, Schrödinger has invested in 3 companies. |
| What was the last Schrödinger investment? | On 13th May 2024 Schrödinger invested in Ajax Therapeutics, participating in a $95M Series C round at $193M valuation, alongside Boxer Capital, EcoR1 Capital, Eli Lilly & Company Foundation, Goldman Sachs Asset Management, Inning One Ventures, Point72 Ventures, RA Capital Management, and Vivo Capital. |
| In what companies Schrödinger invested in? | Schrödinger invested in Ajax Therapeutics, Morphic Therapeutic, and Nimbus Therapeutics. |
See public comps similar to Schrödinger
Lists including Schrödinger
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
